Xtant Medical (NYSE American: XTNT) has announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata. According to Xtant, the nanocrystalline structure of...
AC Immune (NASDAQ: ACIU) has announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy, ACI-7104.056, in early Parkinson’s...
Senti Bio (NASDAQ: SNTI) has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen...
Formycon AG (FSE: FYB, Prime Standard) and closely held MS Pharma have jointly announced that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206—Formycon’s biosimilar...
Greenwich LifeSciences (NASDAQ: GLSI) has announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. FLAMINGO-01 is a Phase III clinical trial designed to evaluate the safety and efficacy...
Moleculin Biotech (NASDAQ: MBRX) has announced that it has entered into a research and material transfer agreement with non-profit CIC biomaGUNE for preclinical research evaluating Annamycin for the treatment of...
Immutep (ASX: IMM; NASDAQ: IMMP) and Dr. Reddy’s Laboratories (BSE: 500124; NSE: DRREDDY; NYSE: RDY; NSEIFSC: DRREDDY) have announced that they have entered into a strategic collaboration and exclusive licensing...
Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the...
Ekso Bionics Holdings (NASDAQ: EKSO) has announced that it has entered into an agreement with Israel-based closely-held MediTouch (MediTouch) to become the exclusive authorized sales agent and distributor of MediTouch’s...
ADC Therapeutics (NYSE: ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in...